NXGL NEXGEL, INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1468929 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.5%
TTM net income YoY-130.7%
TTM EPS YoY-45.3%
Revenue 3-yr CAGR51.6%
Net income 3-yr CAGR—
Margins
Gross margin33.4%
Operating margin-58.6%
Net margin-54.0%
FCF margin—
EBITDA margin-40.4%
Returns
ROE-142.7%
ROA-37.4%
ROIC (approx.)-153.8%
Asset turnover0.69x
Leverage & solvency
Liabilities / assets80.5%
Debt / equity0.00x
Current ratio0.46x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.53x
Accruals ratio-17.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $11.42M | $8.69M |
| Cost of revenue | $6.91M | $5.94M |
| Gross profit | $4.51M | $2.75M |
| R&D expense | $2,000 | $78,000 |
| SG&A expense | $7.86M | $6.22M |
| Operating income | -$3.35M | -$3.55M |
| Interest expense | $34,000 | $81,000 |
| Pretax income | -$2.89M | -$3.46M |
| Net income | -$3.00M | -$3.28M |
| EBITDA | -$2.90M | -$3.12M |
| EPS (basic) | -0.38 | -0.50 |
| EPS (diluted) | -0.38 | -0.50 |
| Weighted avg. shares (diluted) | 7.85M | 6.51M |
| Balance sheet | ||
| Cash & equivalents | $317,000 | $1.81M |
| Receivables | $673,000 | $933,000 |
| Inventory | $2.11M | $1.75M |
| Current assets | $4.34M | $5.11M |
| PP&E, net | $1.96M | $2.21M |
| Goodwill | $1.13M | $1.13M |
| Intangibles | $681,000 | $807,000 |
| Total assets | $10.46M | $10.98M |
| Current liabilities | $2.96M | $2.47M |
| Long-term debt | $588,000 | $685,000 |
| Total debt | $588,000 | $685,000 |
| Total liabilities | $5.57M | $4.90M |
| Shareholders' equity | $4.46M | $5.75M |
| Net debt | $271,000 | -$1.12M |
| Shares outstanding | 407,157 | 7.64M |
| Cash flow statement | ||
| Operating cash flow | -$1.31M | -$3.87M |
| Capital expenditure | $68,000 | $443,000 |
| Free cash flow | -$1.38M | -$4.31M |
| Investing cash flow | -$68,000 | -$775,000 |
| Financing cash flow | $630,000 | $3.75M |
| Depreciation & amortization | $450,000 | $436,000 |
| Stock-based compensation | $654,000 | $367,000 |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.